Drug guidance
Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
Condition
Blood and Immune System
Cancer
2 January 2024
Published on 02 Jan 2024
Last Updated on 02 Jan 2024
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion, in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin and prednisone, for previously untreated diffuse large B-cell lymphoma (DLBCL) with an international prognostic index (IPI) score of 3 to 5.
Funding status
Polatuzumab vedotin 30 mg and 140 mg powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indication from 1 March 2024.
MAF assistance does not apply to previously untreated diffuse large B-cell lymphoma in patients with an IPI score below 3.
Clinical indications, subsidy class and MediShield Life claim limits for polatuzumab vedotin are provided in the Annex.